a d Non-Hodgkin's Lymphoma: Current Strategies, Ongoing Challenges, and Future Treatments in Follicular Lymphoma | Oncolink - Cancer Resources

Non-Hodgkin's Lymphoma: Current Strategies, Ongoing Challenges, and Future Treatments in Follicular Lymphoma

Faculty : Steven Horwitz, MD. Associate Attending
Memorial Sloan Kettering Cancer Center, New York, NY
Ultima Vez Modificado: 3 de mayo del 2013

Share article


Non-Hodgkin's lymphoma (NHL) is the most common hematologic malignancy in adults, and the sixth most common cancer diagnosed in the United States each year. Upon completion of this activity, participants will be able to: 1)Review recent revisions to NHL treatment guidelines, including updated therapy algorithms, 2) Review the complications associated with treating patients with NHL, and 3) Review the most current data about new therapies, treatment strategies, and combination regimens for NHL.

Continue to Activity


News
FDA Approves Zydelig for Three Types of Blood Cancer

Jul 24, 2014 - Zydelig (idelalisib) has been approved by the U.S. Food and Drug Administration to treat relapsed forms of blood cancer, including chronic lymphocytic leukemia, follicular B-cell non-Hodgkin's lymphoma, and small lymphocytic lymphoma, the FDA said Wednesd



OncoLink Treatment Binder

Seleccione los efectos secundarios y formas de ligante de tratamiento de su paciente

Más información



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.


OncoLink OncoPilot

Frente a un nuevo diagnóstico de cáncer o de cambiar el curso de su tratamiento actual? Deje que nuestro personal de enfermería cáncer que ayudan a pasar!

Más información